New Bulletin No. 11, March 1, 2002
Special Osteoarthritis Symposium planned for Lisbon
The latest information about osteoarthritis will be presented May 14, 2002 from 13.45 to 17.30 at a special symposium "Recent Advances in Osteoarthritis".
Delegates registered for the IOF World Conference on Osteoporosis may attend this special Osteoarthritis Symposium at no additional cost.
Chairmen of the afternoon session, which will be held Tuesday May 14 as part of the IOF World Congress on Osteoporosis, are Dr. Tashin Hadidi from Egypt and Dr. Sergio Jimenez from the United States.
Speakers for the symposium include:
Kristina Akesson, Bone & Joint Decade;Cyrus Cooper, UK; Roland Moskowitz,USA; Charles Peterfy, USA; Pierre D. Delmas, France; Jean-Pierre Pelletier, Canada; Marc Hochberg, USA; Jean-Yves Reginster, Belgium
The symposium is organized by IOF-International Osteoporosis Foundation in collaboration with ILAR-International League of Associations in Rheumatology and OARSI-Osteoarthritis Research Society International. Following the "Recent Advances in Osteoarthritis" symposium, Merck Sharp & Dohme will sponsor an additional symposium "Management of Pain with COX-2 Inhibition".
For more information about this symposium please contact Patricia Bisch, email@example.com
New Bulletin No. 10, February 15, 2002
Call for Late Breaking News
Researchers whose work is just now being completed can still apply to present their results at the IOF World Congress on Osteoporosis.
On Tuesday May 14th, the last oral presentation session will be devoted to the presentation of late-breaking news. These news items will be selected from abstracts that researchers can submit before March 31, 2002.
"We want to accommodate researchers whose work was completed after the first abstract deadline," says Professor Rene Rizzoli, chairman of the IOF World Congress on Osteoporosis Scientific Committee and chairman of the IOF Committee of Scientific Advisers. "We are confident that the 'last-minute' news will yield exciting studies that otherwise wouldn't be available to Congress participants."
Because of printing deadlines, it will not be possible to incorporate these late-breaking abstracts in the abstract book of the congress, but they might be published in a later issue of Osteoporosis International.
New Bulletin No. 9, February 1, 2002
Thirteen cutting-edge satellite symposia will be held at the IOF World Congress on Osteoporosis.
Sponsored by 13 major pharmaceutical companies, the symposia will examine new diagnostic, and treatment options for osteoporosis and osteoarthritis.
Some of the subjects covered:
- From research to clinical evidence: Defining the standard for postmenopausal women
- Optimizing bone formation and resorption with strontium ranelate: An innovative therapeutic approach to osteoporosis
- Risedronate therapy: Current understandings, clinical applications, and future directions
- Protecting bone health with lower HRT doses
- Setting the standard for treating osteoporosis: New evidence for optimal patient management
- New findings on the effect of Alfacalcidol and D-hormone analogs on fractures
- BMD-Myth and reality
- Achieving balance-encouraging your patients
- New options in the treatment of osteoporosis
- Vitamin K and osteoporosis
- The tissue specific approach to osteoporosis
- Managing osteoporosis-one step beyond
- Management of pain with COX-2 inhibition
Corporate sponsors of satellite symposia:
Alliance for Better Bone Health; Chugai, Teijin, and Teva; Eisai; Lilly, Merck, Sharp & Dohme; Novartis; Organon; Pfizer; Roche; Servier, Wyeth-Ayerst
New Bulletin No. 8, January 16, 2002
"Meet the Experts"-Participants and Subjects finalised
Thirty-one of the world's leading osteoporosis experts will lead 24 "Meet the Experts" sessions.
"We hope that these informal, interactive sessions will create new synergies," explains Professor Rene Rizzoli, chairman of IOF's Committee of Scientific Advisors and chairman of the Lisbon congress's scientific committee.
In the "Meet the Experts" sessions, a small group will be encouraged to not only ask questions but to also provide feedback about their own experiences.
The following topics will be covered:
- Clinical use of biochemical markers
- Clinical use of densitometry
- Corticosteroid-induced osteoporosis
- Male osteoporosis
- Transplantation bone diseases
- Translation of epidemiology and clinical trial into practice
- HRT and SERMS
- The role of allied professions
- How to build up an osteoporosis society
- Tools for the evaluation of quality of life in osteoporosis
- Pediatric bone diseases
- Practical management of osteoporosis by region:
North America/ Latin America / Asia / Europe / Middle East
- Health economics
The variety of subjects covered should be of help for practitioners and health care professionals involved in the management and care of patients with osteoporosis.
The sessions will be held each afternoon; for full schedule and names of the experts, see programme.
Plenary Speakers Announced
Bone fragility in children Opportunities of therapy
F. Glorieux, Professor of Surgery & Pediatrics, McGill University, Canada
Why is osteoporosis complicated by fractures?
E. Seeman, Professor, Department of Endocrinology, University of Melbourne, Australia
Contribution of bone biology to the development of new therapy in Osteoporosis
R. Baron, Professor, Department of Cell Biology and Orthopedics, Yale University, USA
Transgenic models to understand osteoporosis
G. Karsenty, Professor, Department of Molecular & Human Genetics, Baylor College of Medicine, USA
New perspectives in osteoporosis treatment
G. Mundy, Professor and Head Division of Endocrinology & Metabolism, University of Texas, USA
Quality of life and burden of osteoporosis
E. Barrett-Connor, Professor and Chief, Division of Epidemiology, Department of Family and Preventive Medicine, University of California, USA
Genetics of complex diseases: the bad and the good genes
S. Ralston, Professor, Department of Medicine and Therapeutics, University of Aberdeen Medical School, UK
Decision making process in the management of osteoporosis: "Can the same tools be used worldwide?"
J. Melton, Michael M. Eisenberg Professor, Mayo Clinic, USA
Meet the Expert-Innovative Exchange of Ideas Planned for Lisbon Congress
Participants at the World Congress on Osteoporosis will be able to talk to the world's leading experts about osteoporosis diagnosis, treatment and care in an informal setting.
"With the 'Meet the Expert' program we hope to break the boundaries that often are created during formal, plenary presentations," notes Professor Rene Rizzoli, Chairman of IOF's Committee of Scientific Advisors and Chairman of the Lisbon congress's scientific committee. 'We want these 'Meet the Expert' sessions to be interactive and enriching for both the expert and the audience."
Each day during the conference eight specialists will lead exchanges on eight key topics. A small group, probably less than 100 people, will be encouraged to not only ask questions but to also provide feedback about their own experiences. "We promise no slides, no computers, no lecturing," adds Dr. Rizzoli.
The 'Meet the Expert' program will complement traditionally-structured major presentations and poster sessions.
Satellite Symposia Sold-Out
Some 18 months before the opening of the IOF World Congress on Osteoporosis all of the eight satellite symposia have been booked. "Demand was so great that we had to add two additional symposia," notes Professor Pierre D. Delmas, President of IOF and chairman of the Congress. "This is, by far, the best response we've had to a major conference at such an early date," he says. Satellite symposium hosts: The Alliance for Better Bone Health (Aventis Pharma and Procter & Gamble Pharmaceuticals), Eli Lilly and Company , Merck Sharp & Dohme, Novartis Pharma AG, N.V. Organon, Pfizer Inc., Servier, Roche, Chugai Pharmaceutical Co / Teijin Ltd. / Teva Pharmaceutical Industries Ltd, Wyeth-Ayerst.
The IOF World Congress on Osteoporosis will take place May 10-14, 2002 in the Lisboa Congress Center, Lisbon, Portugal. The Lisbon event is expected to be the largest scientific congress devoted specifically to osteoporosis ever held, with some 5000 registrations expected and some 700 papers and posters expected to be presented.